Ahmed Abdel-Latif

Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice

Dual SGLT1/2 inhibition reduces atherosclerosis and metabolic syndrome more effectively than selective SGLT2 inhibition and is associated with reprogramming of hepatic lipid metabolism, suggesting that sotagliflozin could be an attractive candidate for mitigating atherosclerotic risk in non-diabetic CKD.